A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer

被引：0
|
作者：
Anthony W. Tolcher
Leonard J. Appleman
Geoffrey I. Shapiro
Alain C. Mita
Frank Cihon
Arthur Mazzu
Pavur R. Sundaresan
机构：
[1] START (South Texas Accelerated Research Therapeutics),Early Drug Development Center, Department of Medical Oncology
[2] University of Pittsburgh Cancer Institute,Department of Medicine
[3] Dana-Farber Cancer Institute,Clinical Statistics
[4] Brigham and Women’s Hospital,Pharmacodynamics
[5] Harvard Medical School,undefined
[6] Institute for Drug Development,undefined
[7] Cancer Therapy and Research Center,undefined
[8] Bayer Healthcare Pharmaceuticals Inc.,undefined
[9] Bayer Healthcare Pharmaceuticals Inc.,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2011年 / 67卷
关键词：
Cardiovascular adverse event (CAE); Left ventricular ejection fraction (LVEF); Hypertension; QT/QTc interval; Sorafenib; Cardiovascular profile;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：751 / 764
页数：13
相关论文
共 50 条
  • [1] A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer
    Tolcher, Anthony W.
    Appleman, Leonard J.
    Shapiro, Geoffrey I.
    Mita, Alain C.
    Cihon, Frank
    Mazzu, Arthur
    Sundaresan, Pavur R.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (04) : 751 - 764
  • [2] A Phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer
    Jones, R. L.
    Bendell, J. C.
    Smith, D. C.
    Deifenbach, K.
    Lettieri, J.
    Boix, O.
    Lockhart, A. C.
    O'Bryant, C. L.
    Moore, K. N.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S336 - S337
  • [3] A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer
    Jones, Robin L.
    Bendell, Johanna C.
    Smith, David C.
    Diefenbach, Konstanze
    Lettieri, John
    Boix, Oliver
    Lockhart, A. Craig
    O'Bryant, Cindy
    Moore, Kathleen N.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (04) : 777 - 784
  • [4] A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer
    Robin L. Jones
    Johanna C. Bendell
    David C. Smith
    Konstanze Diefenbach
    John Lettieri
    Oliver Boix
    A. Craig Lockhart
    Cindy O’Bryant
    Kathleen N. Moore
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 777 - 784
  • [5] Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors
    Gordon, Michael S.
    Nemunaitis, John
    Barve, Minal
    Wainberg, Zev A.
    Hamilton, Erika P.
    Ramanathan, Ramesh K.
    Sledge, George W., Jr.
    Yue, Huibin
    Morgan-Lappe, Susan E.
    Blaney, Martha
    Kasichayanula, Sreeneeranj
    Motwani, Monica
    Wang, Lan
    Naumovski, Louie
    Strickler, John H.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (10) : 1988 - 1995
  • [6] A Phase I, Open-Label Study of Trebananib Combined With Sorafenib or Sunitinib in Patients With Advanced Renal Cell Carcinoma
    Hong, David S.
    Gordon, Michael S.
    Samlowski, Wolfram E.
    Kurzrock, Razelle
    Tannir, Nizar
    Friedland, David
    Mendelson, David S.
    Vogelzang, Nicholas J.
    Rasmussen, Erik
    Wu, Benjamin M.
    Bass, Michael B.
    Zhong, Zhandong D.
    Friberg, Gregory
    Appleman, Leonard J.
    CLINICAL GENITOURINARY CANCER, 2014, 12 (03) : 167 - U95
  • [7] Cardiovascular safety of pimitespib in patients with advanced solid tumors: An open-label, nonrandomized, phase 1 study
    Naoki, Katsuhiko
    Igawa, Satoshi
    Uojima, Haruki
    Tsumura, Hideyasu
    Sengoku, Norihiko
    Karayama, Masato
    Shimomura, Akihiko
    Ohtake, Tohru
    Shio, Yutaka
    Hosokawa, Ayumu
    Komatsu, Yoshito
    Kumagai, Yuji
    CANCER, 2024, 130 (21) : 3745 - 3756
  • [8] OPEN-LABEL PHASE II STUDY OF SORAFENIB plus DACARBAZINE IN PATIENTS WITH ADVANCED METASTATIC MELANOMA
    Gonzalez-Larriba, J. L.
    Guillem, V.
    Marmol, M.
    Valladares, M.
    Arrivi, A.
    Pastor, P.
    Garcia-Garcia, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 246 - 246
  • [9] EFFECT OF SORAFENIB TREATMENT ON LEFT VENTRICULAR EJECTION FRACTION IN CANCER PATIENTS: AN OPEN-LABEL, PHASE I STUDY
    Tolcher, A.
    Appleman, L.
    Mita, A.
    Shapiro, G. I.
    Chihon, F.
    Mazzu, A.
    Sundaresan, P. R.
    ANNALS OF ONCOLOGY, 2008, 19 : 179 - 179
  • [10] Phase II open-label study of sunitinib in patients with advanced breast cancer
    Denise A. Yardley
    E. Claire Dees
    Stephen D. Myers
    Sherry Li
    Paul Healey
    Zhixiao Wang
    Marla J. Brickman
    Jolanda Paolini
    Kenneth A. Kern
    Dennis L. Citrin
    Breast Cancer Research and Treatment, 2012, 136 : 759 - 767
12345